Skip to content
ppharmaranks
Menu

UPADACITINIB vs XELJANZ

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. UPADACITINIB and XELJANZ are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Rating

68/100
64/100

Pharmacy pays

Type

RX
RX

Active ingredient

UPADACITINIB
TOFACITINIB CITRATE

Manufacturer

Dosage forms

Tablet, extended release, Tablet
Solution, Tablet

Drug class

Janus Kinase Inhibitor
Janus Kinase Inhibitor

Boxed warning

Half-life

about 8 to 14 hours (mean terminal elimination half-life)

Treats

Rheumatoid Arthritis
Rheumatoid Arthritis

Frequently asked questions

Which is better-rated, Upadacitinib or Xeljanz?

By our independent rating, Upadacitinib scores higher — 3.4 vs 3.2 out of 5 for Xeljanz. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Upadacitinib and Xeljanz?

Upadacitinib contains Upadacitinib, while Xeljanz contains Tofacitinib Citrate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.